Tsuchiya Takeshi, Ohshima Koichi, Karube Kennosuke, Yamaguchi Takahiro, Suefuji Hiroaki, Hamasaki Makoto, Kawasaki Chika, Suzumiya Junji, Tomonaga Masao, Kikuchi Masahiro
Department of Pathology and Internal Medicine, School of Medicine, Fukuoka University, Fukuoka, Japan.
Blood. 2004 Jan 1;103(1):236-41. doi: 10.1182/blood-2002-05-1352. Epub 2003 Sep 4.
A new World Health Organization classification was recently proposed. However, classification of peripheral T-cell lymphomas remains to be clarified. Particularly, unspecified type was considered as a heterogeneous category. Here we studied the expressions of chemokine receptors, Th1-associated CXCR3 and CCR5 and Th2-associated marker ST2(L), and activated T-cell receptor OX40/CD134 in 185 patients with nodal T-cell lymphoma, and evaluated the relationship to prognosis. Their expression patterns correlated with the specific subtype of nodal T-cell lymphoma, such as angioimmunoblastic T-cell lymphoma (AILD), anaplastic large cell lymphoma (ALCL), and in peripheral T-cell lymphoma (PTCL), unspecified. In AILD, almost all cases were immunoreactive for OX40/CD134 (96%) and for CXCR3 (89%). In ALCL, all cases were immunonegative for OX40/CD134, and only a few cases (24%) were immunoreactive for CXCR3, whereas almost all cases (94%) were positive for ST2(L). Cases of PTCL, unspecified, were divided into 2 groups; group 1 (cases positive for either ST2(L), CCR5, or CXCR3) tended to show favorable prognosis compared with group 2 (cases negative for ST2(L), CCR5, and CXCR3). Our results indicate that further subtyping of PTCL, unspecified, into groups 1 and 2 could be significant for evaluating prognosis and understanding the functional role of these tumors.
世界卫生组织最近提出了一项新的分类。然而，外周T细胞淋巴瘤的分类仍有待明确。特别是，未特指类型被认为是一个异质性类别。在此，我们研究了185例淋巴结T细胞淋巴瘤患者趋化因子受体、Th1相关的CXCR3和CCR5以及Th2相关标志物ST2(L)的表达，以及活化T细胞受体OX40/CD134的表达，并评估了其与预后的关系。它们的表达模式与淋巴结T细胞淋巴瘤的特定亚型相关，如血管免疫母细胞性T细胞淋巴瘤（AILD）、间变性大细胞淋巴瘤（ALCL）以及未特指的外周T细胞淋巴瘤（PTCL）。在AILD中，几乎所有病例对OX40/CD134（96%）和CXCR3（89%）呈免疫反应阳性。在ALCL中，所有病例对OX40/CD134呈免疫阴性，只有少数病例（24%）对CXCR3呈免疫反应阳性，而几乎所有病例（94%）对ST2(L)呈阳性。未特指的PTCL病例分为两组；与第2组（ST2(L)、CCR5和CXCR3均为阴性的病例）相比，第1组（ST2(L)、CCR5或CXCR3为阳性的病例）往往显示出较好的预后。我们的结果表明，将未特指的PTCL进一步分为第1组和第2组对于评估预后和理解这些肿瘤的功能作用可能具有重要意义。
